User talk:Mpuar/Oligonucleotides/Bibliography

Frazier, K. S. (2015). Antisense Oligonucleotide Therapies: The Promise and the Challenges from a Toxicologic Pathologist’s Perspective. Toxicologic Pathology, 43(1), 78–89. https://doi.org/10.1177/0192623314551840

Sinha, N. D., Biernat, J., McManus, J., & Köster, H. (1984). Polymer support oligonucleotide synthesis XVIII: use of beta-cyanoethyl-N,N-dialkylamino-/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. Nucleic acids research, 12(11), 4539–4557. doi:10.1093/nar/12.11.4539

Crooke, S. T. (2017). Molecular Mechanisms of Antisense Oligonucleotides. Nucleic acid therapeutics, 27(2), 70–77. doi:10.1089/nat.2016.0656

Smith, R. A., Bennett, F. C., Cleveland, D. W. (2006). Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest. 116(8):2290-2296. https://doi.org/10.1172/JCI25424

Lundin, K. E., Gissberg O., Smith C.I E. (2015). Oligonucleotide Therapies: The Past and the Present, Human Gene Therapy, Human Gene Therapy, 26(8), doi:10.1089/hum.2015.070

DeVos, S. L., Miller, T. M. (2013). Antisense Oligonucleotides: Treating Neurodegeneration at the Level of RNA. The American Society for Experimental NeuroTheraputics, Inc. 10: 486. https://doi.org/10.1007/s13311-013-0194-5

Eckstein, F. (1985). Nucleoside Phosphorothioates. Annual Reviews Inc. 54:367-402